Early trial outcomes report progression-free survival and response charges for ateganosine, spevatamig, Annamycin and pumitamig; research are at present enrolling.
CURE’s Scientific Trial Nook highlights rising most cancers analysis, giving sufferers and caregivers clear details about new remedy choices. Latest updates embody early information for superior non-small cell lung most cancers, biliary tract most cancers, acute myeloid leukemia and extensive-stage small cell lung most cancers.
Trials are exploring therapies akin to ateganosine with immunotherapy, spevatamig plus chemotherapy, Annamycin mixed with cytarabine, and pumitamig with chemotherapy. These research purpose to judge security, effectiveness and long-term outcomes.
Sufferers involved in studying extra about these trials can use this data as a dialog starter with their healthcare suppliers to find out potential eligibility.
Ateganosine Boosts Lung Most cancers Outcomes
Median progression-free survival was 5.6 months for sufferers with superior non-small cell lung most cancers handled with ateganosine (THIO) plus Libtayo, in response to a information launch from MAIA Biotechnology.
This part 2 THIO-101 trial result’s greater than double the two.5 months seen with normal care. Median general survival reached 17.8 months, and two sufferers have stayed on remedy by means of 33 cycles, suggesting potential for long-term use. Ateganosine targets telomeres, which most cancers cells depend on to outlive, and might also stimulate the immune system.
MAIA is actively enrolling sufferers within the growth part of THIO-101 to additional consider ateganosine’s security and effectiveness.
Spevatamig Trial Begins in Biliary Most cancers
The primary affected person has been handled with spevatamig plus chemotherapy for superior biliary tract most cancers, in response to a information launch from Phanes Therapeutics.
The trial is multi-center and actively enrolling sufferers with superior gastric, gastroesophageal junction, pancreatic ductal, or biliary tract cancers.
This part 2/3 TWINPEAK examine is evaluating the security, tolerability and early effectiveness of spevatamig, a first-in-class bispecific antibody concentrating on claudin 18.2 and CD47. Spevatamig has beforehand acquired orphan drug and quick monitor designations for pancreatic most cancers.
Phanes is finding out spevatamig together with chemotherapy and with different immunotherapies as a part of its rising pipeline of first-in-class antibodies designed to deal with cancers with excessive unmet wants.
Annamycin Examine Expands in AML
Moleculin Biotech is accelerating recruitment in its part 3 MIRACLE trial for adults with relapsed or refractory acute myeloid leukemia (AML), in response to a information launch from the corporate.
The trial is testing Annamycin mixed with cytarabine, often called AnnAraC, throughout websites within the U.S., Europe and the Center East. As of September, 13 sufferers have been handled, enrolled or screened, with a purpose of reaching 20 by month’s finish and 45 within the fourth quarter to permit preliminary unblinding of efficacy and security information.
The examine is actively increasing to new websites in Spain, Georgia, Poland, Romania, Italy, Lithuania and the U.S. Moleculin plans to proceed enrolling sufferers on this adaptive part 2b/3 trial to judge Annamycin’s potential profit in AML.
Pumitamig Reveals Exercise in Small Cell Lung Most cancers
BioNTech and Bristol Myers Squibb reported interim Part 2 information for pumitamig, a PD-L1 x VEGF-A bispecific antibody, in sufferers with extensive-stage small cell lung most cancers, in response to a information launch from the corporate.
Amongst 38 efficacy-evaluable sufferers, pumitamig plus chemotherapy confirmed a 76.3% confirmed general response charge, 100% illness management charge and a median progression-free survival of 6.8 months, with a manageable security profile.
These outcomes assist dose choice for the continuing world pivotal part 3 ROSETTA LUNG-01 trial, which is actively enrolling sufferers throughout the U.S., United Kingdom, Türkiye, China, Republic of Korea and Australia, with extra websites deliberate globally. The trial goals to judge pumitamig plus chemotherapy as a possible new first-line normal of care in extensive-stage small cell lung most cancers.
References
- “MAIA Biotechnology Highlights Optimistic Efficacy Information from THIO-101 Part 2 Scientific Trial in Non-Small Cell Lung Most cancers” by Dr. Vlad Vitoc, GlobeNewswire, September 11, 2025.
- “Phanes Therapeutics Broadcasts First Biliary Tract Carcinoma (BTC) Affected person Dosed in Scientific Examine of Spevatamig in Mixture with Chemotherapy” by Dr. Vera, PR Newswire, September 8, 2025.
- “Moleculin Accelerates Recruitment in Part 3 Acute Myeloid Leukemia ‘MIRACLE’ Scientific Trial” by Dr. Walter Klemp, GlobeNewswire, September 9, 2025.
- “First Disclosure of World Interactions in Oncology Scientific Trials” by Dr. John Doe, GlobeNewswire, September 8, 2025.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
